Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
- 31 December 2005
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 26 (12), 639-644
- https://doi.org/10.1016/j.tips.2005.10.001
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbitsAtherosclerosis, 2005
- Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular MedicineCirculation, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Characterization of the oxidation products of BO-653 formed during peroxyl radical-mediated oxidation of human plasmaFree Radical Biology & Medicine, 2005
- 8‐isoprostane increases scavenger receptor A and matrix metalloproteinase activity in THP‐1 macrophages, resulting in long‐lived foam cellsEuropean Journal of Clinical Investigation, 2004
- COX-2 and beyond: approaches to prostaglandin inhibition in human diseaseNature Reviews Drug Discovery, 2003
- Lipid Peroxidation and the Aging ProcessScience of Aging Knowledge Environment, 2002
- No Effect of Cyclooxygenase Inhibition on Plaque Size in Atherosclerosis-prone MiceScandinavian Cardiovascular Journal, 2002
- The Thromboxane Receptor Antagonist S18886 but Not Aspirin Inhibits Atherogenesis in Apo E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984